ARCA biopharma
8001 Arista Place
Suite 200
Broomfield
Colorado
80021
United States
Tel: 720-940-2100
Fax: 720-208-9261
Website: http://www.arcabiopharma.com/
165 articles with ARCA biopharma
-
GENETIC-AF PHASE 2B CLINICAL TRIAL ATRIAL FIBRILLATION BURDEN (AFB) RESULTS PRESENTED AT AMERICAN HEART ASSOCIATION 2018 SCIENTIFIC SESSIONS
11/12/2018
ARCA biopharma (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that data from the Atrial Fibrillation Burden (AFB) substudy of the Phase 2B GENETIC-AF clinical trial were presented November 11, 2018 in a poster session at the American Heart Association 2018 Scientific Sessions in Chicago.
-
ARCA BIOPHARMA SUBMITS SPECIAL PROTOCOL ASSESSMENT REQUEST TO FDA FOR GENCARO PHASE 3 ATRIAL FIBRILLATION CLINICAL TRIAL
9/18/2018
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it has submitted a Special Protocol Assessment (SPA) request to the U.S. Food and Drug Administration (FDA).
-
ARCA biopharma Announces Second Quarter 2018 Financial Results and Provides Corporate Update
8/9/2018
ARCA biopharma, Inc. reported financial results for the quarter ended June 30, 2018.
-
ARCA Biopharma, located in Westminster, Colorado, announced mixed but positive outcomes from a Phase II clinical trial of its beta-blocker Gencaro for atrial fibrillation (AF) patients with heart failure (HF).
-
ARCA Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting With FDA on Gencaro Development for Atrial Fibrillation
7/31/2018
Single Phase 3 trial may be sufficient for approval of atrial fibrillation indication
-
Arca Biopharma Announces First Quarter 2018 Financial Results and Provides Corporate Update
5/9/2018
ARCA biopharma, Inc. reported financial results for the quarter ended March 31, 2018.
-
ARCA biopharma announced positive headline results from its Phase IIb clinical trial of Gencaro, but investors aren't buying the positive spin.
-
ARCA Biopharma Selects TransPerfect’s Trial Interactive eTMF Solution
2/2/2018
ARCA Biopharma today announced that ARCA biopharma has selected TransPerfect’s Trial Interactive eTMF solution as their enterprise platform for clinical trials.
-
ARCA biopharma Announces Completion of GENETIC-AF Phase IIB Clinical Trial
1/8/2018
ARCA expects to report top-line Phase 2B data in March 2018.
-
ARCA Biopharma Announces Issuance of European Patent for Treating Cardiovascular Diseases and Conditions With a New Chemical Entity Utilizing Genetic Targeting
11/16/2017
The European patent, entitled “Methods and Compositions for Cardiovascular Diseases and Conditions,” provides protection for this novel approach to treating patients with cardiovascular disease and conditions.
-
ARCA biopharma Announces Third Quarter 2017 Financial Results and Provides Business Update
11/10/2017
Cash, cash equivalents and marketable securities totaled $16.0 million as of September 30, 2017, compared to $23.5 million as of December 31, 2016.
-
ARCA biopharma Announces Completion Of Enrollment For GENETIC-AF Phase IIb Clinical Trial
8/16/2017
-
ARCA biopharma Announces Genetic-Af Data And Safety Monitoring Board Recommendation To Complete Phase IIb Genetic-Af Clinical Trial Based On Efficacy And Safety Data In Phase IIb Interim Analysis
8/10/2017
-
ARCA biopharma Announces GENETIC-AF Data And Safety Monitoring Board Recommendation To Complete Phase 2B GENETIC-AF Clinical Trial Based On Efficacy And Safety Data In Phase IIB Interim Analysis
8/10/2017
-
ARCA biopharma Announces Second Quarter 2017 Financial Results and Provides Business Update
8/4/2017
-
ARCA biopharma Announces Database Lock For GENETIC-AF Phase IIB Interim Efficacy Analysis – DSMB Recommendation Anticipated In August 2017
6/20/2017
-
ARCA biopharma Announces First Quarter 2017 Financial Results And Provides Business Update
5/15/2017
-
ARCA biopharma Announces 200th Patient Randomized Into The GENETIC-AF Seamless Design Phase IIB/III Clinical Trial
4/26/2017
-
ARCA biopharma Announces Fiscal Year 2016 Financial Results And Provides Business Update
3/22/2017
-
ARCA biopharma Announces 175th Patient Randomized Into The GENETIC-AF Phase 2B/3 Clinical Trial
3/6/2017